Skip to content

Home - Investors    
Investor relations
We aim to create enduring shareholder value and deliver a sustained financial performance that will match the best in the industry.
Latest news
> 14 May 2008 : FDA Approves AstraZeneca’s Seroquel for Maintenance Treatment in Bipolar Disorder
> 8 May 2008 : AstraZeneca Submits sNDA for Seroquel XR™ for the Treatment of Generalised Anxiety Disorder – a First for the Atypical Antipsychotic Class of Medicines
> 6 May 2008 : EPO Announces Symbicort® European COPD Use Patent Decision
> Read more news articles
Latest result announcements
> 24 April 2008 : First quarter results 2008
> 31 January 2008 : Fourth quarter and full year results 2007
> 1 November 2007 : Third quarter and nine months results
> 26 July 2007 : Second quarter and half year results 2007
Features
> Annual Report and Form 20-F Information published, Thursday 6 March, and available online as a dedicated website
> Information on Merck arrangements
> Updated R&D pipeline summary following our fourth quarter and full year results 2007
 
Dividends
> Dividend policy and current/historical dividend data
AstraZeneca websites
Search
Quick links
Share price
> London
> New York
> Stockholm
Stock symbol - AZN
On LSE, NYSE and OMX  
AstraZeneca news feed
Email alerts
Order a report
>Online order form
Tel: +44 (0)1707 256 677
 Terms of use  Privacy policy    © AstraZeneca PLC 2003 - 2008